1. Determina 662/2013, G.U. n.175 del 27/07/2013
2. Determina G.U. 41/42 del 24/02/2007
3. Determina G.U. 195 del 21/08/2013
4. Determina G.U. 278 del 28/11/2017
5. Cosmi B. Management of superficial vein thrombosis. J Thromb Haemost 2015; 13: 1175–83
6. Scott G, Mahdi AJ, Alikhan R. Superficial vein thrombosis: a current approach to management. British Journal of Haematology, 2015; 168: 639–64
7. Delavenne X, Frappe´P, Zufferey P et al. PK evaluation of fondaparinux sodium for the treatment of thrombosis. Expert Opin Drug Metab Toxicol 2014; 10 (2)
8. RCP ARIXTRA 2,5 mg 
9. Decousus H, Prandoni P, Mismetti P et al. for the CALISTO Study Group. Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. N Engl J Med 2010; 363:1222-32
10. Beyer-Westendorf J, et al Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017; 4(3):e105-e113
11. Blin P, Sevestre MA, Pouchain D, Gillet JL.Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: A real-world cohort study. Thrombosis Research 2017; 157:117-119
12. Duffett L et al. Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thromb Haemost 2019;119(3):479-489 
13. Milio G et al. Modello di percorso diagnostico e terapeutico per la trombosi venosa superficiale. Minerva Cardioangiol 2012; 60(Suppl. 4 al N. 2):37-50
14. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2) (Suppl):e419S–e494S
15. Airoldi G, Campanini M. Fondaparinux. Italian Journal of Medicine 2008;2(1):44-52
16. Turpie AGG. Selective factor Xa inhibition with Fondaparinux: from concept to clinical benefit. European Heart Journal Supplements 2008; 10 (Supplement C), C1–C7
17. RCP ARIXTRA 5 mg
18. RCP ARIXTRA 7,5 mg
19. RCP ARIXTRA 10 mg
20. RCP ARIXTRA 1,5 mg